FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Nicholas Moore

Research Profile

Chemicals & Drugs

Living Beings

Rats
Mouse

Concepts & Ideas

Drug Dose Response Relationship

Activities & Behaviors

Disorders

Catalepsy

Physiology

Avoidance Learning

Co-author Network

Publications

TOP 3
Abegale W Hartfield; Nicholas Moore; Peter G Clifton
Effects of atypical antipsychotic drugs on intralipid intake and cocaine-induced hyperactivity in rats.
Kurt Rasmussen; Mark J Benvenga; Frank P Bymaster; David O Calligaro; Ilene R Cohen; Julie F Falcone; Susan K Hemrick-Luecke; Fionna M Martin; Nicholas Moore; Laura K Nisenbaum; John M Schaus; Sarah J Sundquist; David E Tupper; Todd R Wiernicki; David L Nelson
Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapine.
Graham H Timms; John Boot; Richard J Broadmore; Stepheb Carney; Jane Cooper; Jeremy D Findlay; Jeremy Gilmore; Stephen Mitchell; Nicholas Moore; Ian A Pullar; Graham J Sanger; Rosemarie Tomlinson; Beverly B Tree; Susan Wedley
SAR development of a selective 5-HT1D antagonist/serotonin reuptake inhibitor lead using rapid parallel synthesis.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Nicholas Moore (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2006: Abegale W Hartfield; Nicholas Moore; Peter G Clifton
Effects of atypical antipsychotic drugs on intralipid intake and cocaine-induced hyperactivity in rats.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2006;31(9):1938-45.
2005: Kurt Rasmussen; Mark J Benvenga; Frank P Bymaster; David O Calligaro; Ilene R Cohen; Julie F Falcone; Susan K Hemrick-Luecke; Fionna M Martin; Nicholas Moore; Laura K Nisenbaum; John M Schaus; Sarah J Sundquist; David E Tupper; Todd R Wiernicki; David L Nelson
Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapine.
The Journal of pharmacology and experimental therapeutics 2005;315(3):1265-77.
2004: Graham H Timms; John Boot; Richard J Broadmore; Stepheb Carney; Jane Cooper; Jeremy D Findlay; Jeremy Gilmore; Stephen Mitchell; Nicholas Moore; Ian A Pullar; Graham J Sanger; Rosemarie Tomlinson; Beverly B Tree; Susan Wedley
SAR development of a selective 5-HT1D antagonist/serotonin reuptake inhibitor lead using rapid parallel synthesis.
Bioorganic & medicinal chemistry letters 2004;14(10):2469-72.
2003: Lorraine Axford; John Boot; Terrence M Hotten; Martine Keenan; Fionna M Martin; Sandra Milutinovic; Nicholas Moore; Michael F O'Neill; Ian A Pullar; David E Tupper; Kristel R Van Belle; Vincent Vivien
Bicyclo[2.2.1]heptanes as novel triple re-uptake inhibitors for the treatment of depression.
Bioorganic & medicinal chemistry letters 2003;13(19):3277-80.
2003: Abegale W Hartfield; Nicholas Moore; Peter G Clifton
Serotonergic and histaminergic mechanisms involved in intralipid drinking?
Pharmacology, biochemistry, and behavior 2003;76(2):251-8.
2003: Michael F O'Neil; Nicholas Moore
Animal models of depression: are there any?
Human psychopharmacology 2003;18(4):239-54.
2003: Abegale W Hartfield; Nicholas Moore; Peter G Clifton
Effects of clozapine, olanzapine and haloperidol on the microstructure of ingestive behaviour in the rat.
Psychopharmacology 2003;167(2):115-22.
2002: In-Won Chung; Nicholas Moore; Won-Keun Oh; Michael F O'Neill; Jong Seog Ahn; Joo-Bae Park; Ung Gu Kang; Yong Sik Kim
Behavioural pharmacology of polygalasaponins indicates potential antipsychotic efficacy.
Pharmacology, biochemistry, and behavior 2002;71(1-2):191-5.
1999: Nicholas Moore; G Rees; J A Monn
Effects of the group II metabotropic glutamate receptor agonist, LY354740 on schedule-controlled behaviour in rats.
Behavioural pharmacology 1999;10(3):319-25.
1999: Nicholas Moore
Behavioural pharmacology of the new generation of antipsychotic agents.
The British journal of psychiatry. Supplement 1999;(38):5-11.
1999: Nicholas Moore
Olanzapine: preclinical pharmacology and recent findings.
The British journal of psychiatry. Supplement 1999;(37):41-4.
1999: Frank P Bymaster; K W Perry; David L Nelson; David T Wong; Kurt Rasmussen; Nicholas Moore; David O Calligaro
Olanzapine: a basic science update.
The British journal of psychiatry. Supplement 1999;(37):36-40.
1997: Nicholas Moore; J David Leander; Mark J Benvenga; Scott D Gleason; H Shannon
Behavioral pharmacology of olanzapine: a novel antipsychotic drug.
The Journal of clinical psychiatry 1997;58 Suppl 10():37-44.
1997: Frank P Bymaster; Kurt Rasmussen; David O Calligaro; David L Nelson; Neil DeLapp; David T Wong; Nicholas Moore
In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug.
The Journal of clinical psychiatry 1997;58 Suppl 10():28-36.
1996: Frank P Bymaster; David O Calligaro; Julie F Falcone; R D Marsh; Nicholas Moore; N C Tye; Philip Seeman; David T Wong
Radioreceptor binding profile of the atypical antipsychotic olanzapine.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1996;14(2):87-96.
1993: Nicholas Moore; G Rees; G Sanger; L Perrett
5-HT1A-mediated lower lip retraction: effects of 5-HT1A agonists and antagonists.
Pharmacology, biochemistry, and behavior 1993;46(1):141-3.
1993: Nicholas Moore; G Rees; G Sanger; S Awere
Effect of L-type calcium channel modulators on stimulant-induced hyperactivity.
Neuropharmacology 1993;32(7):719-20.
1993: Nicholas Moore; A Blackman; S Awere; J D Leander
NMDA receptor antagonists inhibit catalepsy induced by either dopamine D1 or D2 receptor antagonists.
European journal of pharmacology 1993;237(1):1-7.
1992: Nicholas Moore; N C Tye; M S Axton; F C Risius
The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent.
The Journal of pharmacology and experimental therapeutics 1992;262(2):545-51.
1990: Nicholas Moore; M S Axton
The role of multiple dopamine receptors in apomorphine and N-n-propylnorapomorphine-induced climbing and hypothermia.
European journal of pharmacology 1990;178(2):195-201.
1988: Nicholas Moore; M S Axton
Production of climbing behaviour in mice requires both D1 and D2 receptor activation.
Psychopharmacology 1988;94(2):263-6.